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SPulmonary complications after lung resection in the absence
of chronic obstructive pulmonary disease: The predictive role
of diffusing capacity
Mark K. Ferguson, MD,a Henning A. Gaissert, MD,b Joshua D. Grab, MS,c and Shubin Sheng, MSc
Objective: Diffusing capacity is not routinely used in assessing risk of lung resection, perhaps owing to
uncertainty as to whether patients with normal spirometric results require additional evaluation. We determined
whether diffusing capacity is predictive of pulmonary complications after lung resection in patients with normal
spirometric results.
Methods:We reviewed outcomes of major lung resection in The Society of Thoracic Surgeons General Thoracic
Surgery Database from 2002 to 2008 to determine the relationship of diffusing capacity (expressed as percent of
predicted) to postoperative pulmonary complications stratified by chronic obstructive pulmonary disease status.
Results: Percent of predicted diffusing capacity was measured in 7891 (57%) patients. There were 3905 women
and 3986 men with a mean age of 66.3  10.6 years who underwent lobectomy (6904; 87.5%), bilobectomy
(463; 5.9%), and pneumonectomy (524; 6.6%). Chronic obstructive pulmonary disease was identified in
2711 (34.4%) patients. Pulmonary complications occurred in 13%, and the operative mortality was 1.9%. Per-
cent of predicted diffusing capacity was strongly associated with the development of pulmonary complications
(odds ratio, 1.12 per 10-point decrease; P< .0001). Decreasing percent of predicted diffusing capacity was
incrementally related to an increased incidence of pulmonary complications regardless of chronic obstructive
pulmonary disease status. There was no apparent interaction between percent of predicted diffusing capacity
and chronic obstructive pulmonary disease status in the predictive model.
Conclusions: Percent of predicted diffusing capacity predicts pulmonary complications after lung resection
in patients without chronic obstructive pulmonary disease. We recommend measurement of diffusing capacity
in lung resection candidates, regardless of chronic obstructive pulmonary disease, as an important element in
the accurate assessment of operative risk. (J Thorac Cardiovasc Surg 2009;138:1297-302)
GENERALTHORACIC SURGERYPulmonary complications are among the most common
causes of postoperative morbidity after major lung resection.
They are associated with increased operative mortality and
hospital cost.1 Although spirometry and diffusing capacity
of the lung for carbon monoxide (DLCO) were both shown
in the 1950s to be importantly reduced after major lung
resection,2-4 the use of DLCO has not become routine in
assessing operative risk for major lung resection. In the
European Thoracic Surgery Database, 77% of patients
underwent major lung resection without measurement of
DLCO.5 It is not knownwhether this is owing to lack of access
to qualified pulmonary function laboratories, cost concerns,
or the impression that patients with normal spirometric re-
sults do not require the additional measurement of DLCO.
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doi:10.1016/j.jtcvs.2009.05.045The Journal of Thoracic and CTwo recent reports demonstrate that DLCO is an important
and independent predictor of postoperative complications
after major lung resection, even in patients without chronic
obstructive pulmonary disease (COPD).6,7 Both reports
were based on review of outcomes from single institutions,
raising concerns about how generalized the findings and rec-
ommendations are. The recent advent of The Society of Tho-
racic Surgeons (STS) General Thoracic Surgery Database
provides an ideal opportunity to explore the utility of
DLCO measurement in the general population of patients un-
dergoing major lung resection for cancer. Using the STS da-
tabase, we sought to determine the relative predictive value
of DLCO in patients with and without COPD.
METHODS
Outcomes of major lung resection in the STS General Thoracic
Surgery Database from January 2002 through June 2008 were reviewed.
Patients were selected who had a diagnosis of primary lung cancer and
who underwent major lung resection (lobectomy, sleeve lobectomy,
bilobectomy, or pneumonectomy). Exclusion criteria were as follows:
concomitant chest wall resection, extrapleural pneumonectomy, carinal
sleeve pneumonectomy, completion pneumonectomy, and emergency or
urgent operation. Demographic and surgical information was abstracted
from the database for analysis. COPD was defined as FEV1/FVC<0.7
(FEV1, forced expiratory volume in the first second; FVC, forced vital
capacity) and FEV1%< 80, which corresponds to moderate to severe
COPD by international criteria.8 Patients without COPD were classifiedardiovascular Surgery c Volume 138, Number 6 1297
General Thoracic Surgery Ferguson et al
G
T
SAbbreviations and Acronyms
ASA ¼ American Society of Anesthesiolgists
COPD ¼ chronic obstructive pulmonary disease
DLCO ¼ diffusing capacity of the lung for carbon
monoxide
FEV1 ¼ forced expiratory volume in the first
second
FVC ¼ forced vital capacity
STS ¼ The Society of Thoracic Surgeons
as ‘‘normal’’ (FEV1/FVC0.7 and FEV1% > 80) or ‘‘not normal/no
COPD’’ (FEV1/FVC<0.7 or FEV1%<80, but not both). Some categorical
variables (performance status, American Society of Anesthesiolgists
[(ASA] score) were dichotomized, whereas resection type was organized
into 3 categories: lobectomy, bilobectomy or sleeve lobectomy, and pneu-
monectomy. Staging was done according to the American Joint Commis-
sion on Cancer.9 The study end point was pulmonary complications,
defined as atelectasis necessitating bronchoscopy, pneumonia, adult respira-
tory distress syndrome, bronchopleural fistula, initial ventilator support
necessary for more than 48 hours, tracheostomy, reintubation for any rea-
son, or any other pulmonary complication.
Patients with insufficient data, primarily DLCO (expressed as a percent of
predicted), were omitted from the analysis. Univariate analyses were per-
formed by c2 analysis for categorical variables and the unpaired Student t
test for continuous variables. Mulitvariable analyses included logistic re-
gression methods using generalized estimating equations to account for
within-site (ie, hospital) correlation of patients. Interaction terms were con-
structed to explore independence of variables in the models. Continuous
data are expressed as mean  SD.
A waiver for this study was granted by The University of Chicago Inter-
nal Review Board.
RESULTS
Records were available for 14,160 patients operated on at
107 participating sites during the period of study. Of these,
2.3% had spirometric data that were considered inaccurate.
Of the remaining 13,839 patients, 7891 (57%) had sufficient
DLCO data and were used in the analyses. Criteria for COPD
were present in 2711 (34.4%) patients, 2672 (33.8%) pa-
tients had normal spirometric data, and 2508 (31.8%)
were classified as not normal/no COPD. There were few
clinically important differences between the groups of pa-
tients with and without values for DLCO (Table 1). Patients
with DLCO measurement were more advanced in mean age,
more likely to have hypertension and to receive induction
therapy, and had higher mean FVC and FEV1 values.
DLCO measurement, however, was also associated with
a lower mean FEV1/FVC ratio and a greater proportion of
patients with COPD. Operations in the study group included
lobectomy in 6904 (87.5%), sleeve lobectomy or
bilobectomy in 463 (5.9%), and pneumonectomy in 524
(6.6%). The majority of patients in the study group had
T1 or T2 tumors (84.5%) and no nodal involvement
(69.1%). The incidence of pulmonary complications in the
study group was 13%, and 1.9% of patients had operative1298 The Journal of Thoracic and Cardiovascular Sumortality (Table 2). The incidences of pulmonary complica-
tions and operative mortality did not differ between groups
with and without DLCO measurements.
Univariate analyses identified a number of variables that
were associated with pulmonary complications, including
age, sex, performance status, ASA class, cardiovascular dis-
ease, pulmonary dysfunction, other organ dysfunction, and
the extent of the operation (Table 3). Logistic regression
analysis identified age, performance status, ASA class, con-
gestive heart failure, renal insufficiency, a recent smoking
history, induction therapy, the extent of resection,
FEV1%, and DLCO as significant predictors of pulmonary
complications (Table 4). Age, induction therapy, the extent
of surgery, and DLCO% were the preoperative clinical vari-
ables most strongly associated with the development of
TABLE 1. Comparison of patient populations with and without
measurement of DLCO
Parameter
DLCO not measured
(5948 patients)
DLCO measured
(7891 patients) P value
Mean age (y) 65.8  11.0 66.3  10.6 .018
Male 3000 (50.4%) 3986 (50.5%) .93
Performance status
0 or 1
5063/5427 (93.9%) 7177/7682 (93.4%) .76
ASA class I to III 4905/5443 (90.1%) 6860/7580 (90.5%) .46
BMI 27.2  5.9 27.2  6.0 .18
Hypertension 3161/5927 (53.3%) 4383/7855 (55.8%) .004
Coronary artery
disease
1206/5894 (20.5%) 1633/7781 (21.0%) .45
Congestive heart
failure
171/5880 (2.9%) 247/7743 (3.2%) .35
Diabetes mellitus 824/5867 (14.0%) 1122/7805 (14.4%) .58
Renal insufficiency 129/5899 (2.2%) 192/7854 (2.4%) .32
Recent smoking
history
1662/5911 (28.1%) 2154/7828 (27.5%) .44
Preoperative
chemotherapy
408/5805 (7.0%) 633/7700 (8.2%) .01
Preoperative
radiotherapy
292/5864 (5.0%) 444/7703 (5.8%) .046
FVC% 85.8  20.6 88.8  18.1 <.001
FEV1% 78.8  21.7 80.3  20.9 .01
FEV1/FVC 0.69  0.12 0.68  0.11 <.001
COPD 686/2165 (31.7%) 2711/7891 (34.4%) .02
Procedure
Pneumonectomy
Bilobectomy/sleeve
lobectomy
Lobectomy
357 (6.0%)
356 (6.0%)
5235 (88.0%)
524 (6.6)
463 (5.9%)
6904 (87.5%)
.31
Pulmonary
complications
723/5948 (12.2%) 1028/6863 (13.0%) .13
Operative mortality 130/5948 (2.2%) 152/7891 (1.9%) .29
Performance status, Zubrod performance status; DLCO, diffusing capacity of the lung
for carbon monoxide; ASA, American Society of Anesthesiology; BMI, body mass
index; recent smoking history, quit cigarette use less than 30 days before the operation;
FVC, forced vital capacity; FEV1, forced expiratory volume in the first second; COPD,
chronic obstructive pulmonary disease, defined as FEV1/FVC ratio<0.7 and
FEV1%<80.rgery c December 2009
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an interaction variable to explore the relationship between
DLCO and COPD status, the strongest predictors of pulmo-
nary complications (including DLCO%) were unchanged, in-
dicating COPD status did not influence the predictive ability
of DLCO% with regard to pulmonary complications. A par-
simonious model of pulmonary complications was devel-
oped using backward selection (P ¼ .05) and accounting
for interactions between DLCO%, FEV1%, and FVC%. In-
dependent predictors of pulmonary complications and their
odds ratios were similar to the nonparsimonious model.
The variables with the greatest statistical significance were
age, induction therapy, FEV1%, DLCO%, extent of
resection, and a recent smoking history.
The incidence of DLCO% less than 60 was 25.7% overall
and was 12.4%, 26.3%, and 42.3% in the normal, not nor-
mal/no COPD, and COPD groups, respectively. Figure 1 il-
lustrates the incidence of pulmonary complications by DLCO
group for patients related to COPD status. The frequency of
pulmonary complications increased markedly as DLCO% de-
creased (P< .001 for all patients and for each COPD status
group). At the extremes of DLCO (DLCO%>90 or DLCO%<
60), there were no differences in the risk of pulmonary com-
plications within each COPD status category. However, for
the DLCO% categories 60 to 74 and 75 to 89, there was a sig-
nificant, increasing risk of pulmonary complications pro-
gressing from patients with normal spirometric data to
those with COPD (P ¼ .003 for each).
COMMENT
The ability to predict complications after an operation as
common as major lung resection has important ramifications
for patients, caregivers, medical research, and the health care
industry. Accurate predictive models can enhance communi-
cation between patients and their surgeons, may indicate
when preoperative intervention is indicated to reduce risk,
can help determine whether parenchyma-sparing procedures
rather than anatomic lobectomy are appropriate, and may
TABLE 2. Incidence of pulmonary complications
Category Affected Percent
Any pulmonary complication 1028/7891 13.0
Atelectasis requiring bronchoscopy 321/7828 4.1
Pneumonia 326/7826 4.2
Adult respiratory distress
syndrome (ARDS)
97/7815 1.2
Bronchopleural fistula 34/7812 0.4
Air leak>5 d 798/7790 10.2
Initial ventilator support>48 h 50/7816 0.6
Reintubation 282/7821 3.6
Tracheostomy 101/7819 1.3
Other pulmonary complication 387/7824 4.9The Journal of Thoracic and Cimprove patient selection. Such models also permit risk
stratification for quality improvement and clinical research
and allow improved allocation of limited clinical resources.
Risk modeling for major lung resection is a burgeoning
and increasingly complex field. Until recently, relatively
small databases that were usually based at a single institution
TABLE 3. Univariate analysis of factors associated with pulmonary
complications
Parameter
No complications
(6863 patients)
Complications
(1028 patients) P value
Mean age (y) 66.1  10.6 67.7  10.3 <.001
Male 49.0% 52.8% .022
Zubrod performance
status
0
1
2
3 or 4
44.9%
49.0%
4.8%
1.3%
40.4%
49.4%
8.2%
2.0%
<.001
ASA class
I
II
III
IV or V
1.8%
24.1%
65.3%
8.8%
0.7%
15.3%
69.8%
14.2%
<.001
BMI 27.3  5.8 26.8  5.8 .002
Hypertension 55.2% 59.5% .011
Coronary artery
disease
20.2% 26.0% <.001
Congestive heart
failure
2.8% 5.8% <.001
Diabetes mellitus 13.9% 17.5% .003
Renal insufficiency 2.1% 4.4% <.001
Recent smoking
history
26.7% 33.0% <.001
Preoperative
chemotherapy
7.8% 11.3% <.001
Preoperative
radiotherapy
5.3% 8.6% <.001
FVC% 89.2  18.1 86.1  17.8 <.001
FEV1% 81.1  20.9 75.0  19.8 <.001
FEV1/FVC 0.68  0.11 0.66  0.12 <.001
COPD status
Normal spirometry
Not normal/no COPD
COPD
35.3%
31.8%
32.9%
23.9%
31.8%
44.3%
<.001
DLCO% 75.0  22.2 67.4  20.5 <.001
Procedure
Pneumonectomy
Bilobectomy/
sleeve lobectomy
Lobectomy
6.7%
5.5%
87.8%
6.1%
8.5%
85.4%
<.001
ASA, American Society of Anesthesiology; FVC, forced vital capacity; FEV1, forced
expiratory volume in the first second; BMI, body mass index; recent smoking history,
quit cigarette use less than 30 days before the operation; COPD, chronic obstructive
pulmonary disease defined as FEV1/FVC<0.7 and FEV1%<80; normal spirometry,
FEV1/FVC0.7 and FEV1%> 80; DLCO, diffusing capacity of the lung for carbon
monoxide.ardiovascular Surgery c Volume 138, Number 6 1299
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on these data were characterized by poor predictive ability
because of limited statistical power, missing clinical vari-
ables, or small numbers of complications. Their applicability
to more general populations was therefore questioned. The
recent creation of national and international databases for
thoracic surgery, such as the European Thoracic Surgery
Database, Epithor (French Society of Thoracic and Cardio-
Vascular Surgery), and the STS General Thoracic Surgery
Database, opens the field to new possibilities of risk
prediction and improved outcomes for major lung resection.
As these databases grow and predictive modeling based
on their data improves, how will this information be used?
It is interesting to note how the development of other models
of risk of pulmonary surgery has affected surgeon behavior
in the recent past. Until the 1990s, models for risk of major
lung resection accounted for only 12% to 22% of operative
mortality.10,11 DLCO was identified in 1988 as a strong,
independent predictor of morbidity after major lung resec-
tion.12 The utility of DLCO in assessing risk was confirmed
by a number of other authors.13-16 Despite the recognition
of DLCO as the single strongest predictor of pulmonary mor-
bidity and operative mortality after major lung resection,
surgeons have been slow to adopt its use in the routine
assessment of patients for lung resection. In the European
Thoracic Database, less than 25% of patients undergoing
lung resection had a preoperative DLCO measured.5 In the
TABLE 4. Logistic regression analysis of pulmonary complications
Parameter Odds ratio Lower CI Upper CI P value
Age 1.01 1.01 1.02 <.0001
Male 1.13 0.97 1.32 .13
Performance status2 1.56 1.10 2.21 .014
ASA class IV or V 1.26 1.04 1.51 .017
Hypertension 1.01 0.88 1.17 .84
Coronary artery disease 1.11 0.93 1.34 .25
Congestive heart failure 1.58 1.20 2.10 .0014
Diabetes mellitus 1.18 0.98 1.41 .079
Renal insufficiency 1.53 1.10 2.15 .012
Recent smoking history 1.30 1.14 1.50 .0001
Preoperative chemotherapy
and/or radiotherapy
1.51 1.27 1.8 <.0001
FVC% 1.00 1.00 1.01 .22
FEV1% 0.99 0.98 1.00 .005
Spirometry not normal/no
COPD
1.09 0.91 1.31 .36
COPD 1.16 0.94 1.43 .16
DLCO% (10 point decrease) 1.12 1.09 1.16 <.0001
Pneumonectomy 0.92 0.71 1.20 .56
Bilobectomy or sleeve
lobectomy
1.62 1.28 2.06 <.0001
CI, Confidence interval; ASA, American Society of Anesthesiology; recent smoking
history, quit cigarette use less than 30 days before the operation; COPD, chronic ob-
structive pulmonary disease defined as FEV1/FVC<0.7 and FEV1%>80; DLCO, dif-
fusing capacity of the lung for carbon monoxide.1300 The Journal of Thoracic and Cardiovascular SSTS General Thoracic Surgery Database, we found that
DLCO was reported for fewer than 60% of patients undergo-
ing major lung resection. This attitude is supported by pub-
lished algorithms that do not include DLCO as an initial
screening measure for lung resection candidates.17,18
Possible reasons for omitting DLCO as part of routine
preoperative evaluation include limited access to testing
facilities, concerns about cost-effectiveness, lack of aware-
ness of the predictive ability of this test, use of other
predictive tests such as exercise capacity in lieu of DLCO,
perceived lack of impact on clinical recommendations, and
perceived lack of utility in the setting of normal spirometry.
This study explored the question of whether DLCO has
predictive ability for pulmonary complications after major
lung resection in patients with normal spirometric results.
Recent publications from single institutional data found
that risk associated with DLCO was independent of whether
patients had COPD.6,7 Because findings from such reports
may not be applicable to the general population, in this study
a national database was queried to determine whether DLCO
independently predicts risk regardless of COPD status.
The data for this study came from 107 centers that may
represent a self-selected group of surgeons and medical cen-
ters with interest in tracking clinical activity and outcomes.
Reasons for why some patients had DLCO reported and
others did not are unclear; the population of patients with
DLCO measured was somewhat older with a higher incidence
of risk factors such as hypertension, induction therapy, and
COPD. Interestingly, the patients without DLCO measure-
ments had worse spirometric data, suggesting that the deci-
sion to measure DLCO is not based on the clinical impression
or actual measurement of lung volumes and flows. Out-
comes of surgery were quite good, with 13% of patients
having postoperative pulmonary complications and only
1.9% of patients having operative mortality. We found
that, regardless of COPD status, DLCO was a strong
FIGURE 1. Risk of pulmonary complications relative to diffusing capacity
(DLCO) and chronic obstructive pulmonary disease (COPD) status.urgery c December 2009
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after major lung resection. The results are similar to those
reported from independent centers.6,7 The results of this
study confirm the general applicability of using DLCO as
a routine measure of risk in the preoperative assessment of
lung resection candidates regardless of COPD status.
There are several potential weaknesses in this study.
The data set may not be reflective of the general popula-
tion of patients who undergo major lung resection in the
United States. Because the STS General Thoracic Surgery
Database does not have an auditing feature, whether the
data are accurate and reflect all of the patients treated at
participating sites are unknown. A large number of pa-
tients were excluded from this study because information
on DLCO was lacking. Whether this information was lack-
ing because it was never obtained or because it was not en-
tered into the database is not certain. A number of
differences existed between the groups of patients with
and without DLCO measurements, some of which were
important in the predictive models for pulmonary compli-
cations.
In summary, we found that DLCO is an independent and
strong predictor of the risk of pulmonary complications in
patients undergoing major lung resection for cancer and
that this predictive ability exists regardless of COPD status.
The lack of DLCO measurement was associated with worse
spirometric results, suggesting the possibility that physicians
who do not measure DLCO routinely before major lung resec-
tion may have indications for its measurement other than or
in addition to spirometric findings. Surgeons who elect to
forego measurement of DLCO on the basis of the absence
of classic findings of COPDwill fail to identify an important
abnormality in this factor in up to 25% of patients. We
recommend measurement of DLCO in candidates for lung
resection as an important element in the accurate assessment
of operative risk.
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Discussion
Dr Kemp Kernstine (Duarte, Calif). This is a very important
study using the STS database, our database, to demonstrate that
the DLCO measurement is correlated with complications after lung
resection. This correlation was not solely in patients with COPD,
but in patients without COPD as well. What your findings tell us
is that DLCO should be measured in all patients whether they have
COPD or not, because DLCO independently is correlated with the
postoperative lung resection complication rate.
I have a couple of questions or comments. Currently, the cardiac
and congenital heart surgery databases have a quality assurance
system that is a component of each and the thoracic database
does not. Do you think that this might affect your results?
Dr Ferguson. It is true that there can be concerns raised by the
quality of the data submitted and the selection of data submitted,
and we have no way of assessing that. I think it is appropriate to
keep those concerns in mind when interpreting the data and the
results of our analysis.
Dr Kernstine. Do you recommend then that we should
encourage the STS to have a quality assurance system in our
thoracic data base?
Dr Ferguson. Absolutely.
Dr Kernstine. Then is the DLCO sufficiently standardized across
hospitals to make a generalized recommendation that all thoracic
surgeons should be performing DLCO routinely?
Dr Ferguson. It is a bit of an issue. We have found anecdotally
that the occasional patient comes to us with marginal DLCO and
whenwemeasure it, it is actually a little bit better. There are a number
of potential explanations for that. One is that there are differences inardiovascular Surgery c Volume 138, Number 6 1301
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somepatients have had improvement, for example, in the pneumonia
that they presented with to the outside physicians that led to the in-
vestigation for possible lung cancer, resulting in an improved
DLCO on remeasurement. At least a couple of studies have performed
repeatedmeasurements on healthy patients over time, demonstrating
that, on average, the difference in DLCO measurement was about 1
percentage point. I think, in general, measurements of DLCO are
very reliable. It is not effort related on the part of the patient and it
is not subject to interpretation by someone who is reporting the
results, so on the basis of that I think it is very reliable.
Dr David Follette (Sacramento, Calif). Dr Ferguson, I com-
pletely agree with your conclusions. I do have 3 questions for you.
In a patient with COPD, it is not only DLCO but the corrected
DLCO. Is there anyway through the database that you can tellwhether
these were just the numbers or whether they were the corrected
numbers, because it can make a difference in a COPD population.
Dr Ferguson. It does make a difference and there is no way of
telling in the database which it is. If there is a difference, it is
primarily related to hemoglobin of the patient and generally gets
better if you use the corrected value than the uncorrected value,
but we have no way of distinguishing which value was reported.
Dr Follette. I found that the second and more useful test, espe-
cially coupled with the DLCO, is the carbon dioxide level on a blood
gas. A slight carbon dioxide retention and marked depression in
DLCO, in my view, is the highest risk pulmonary resection candidate
that I deal with. In the database, do they report blood gas data and
did you happen to correlate PCO2 levels with the DCLO?
Dr Ferguson. That is a good question and I agree with your gen-
eral assessment, but I do not recall whether there were blood gas
values. Certainly we did not perform any correlation between those
two. In my own institution, for example, we probably get blood gas
information on only about 30% of patients, so it is not done routinely.
Dr Follette. I know you did not present it, but I would like your
guideline as to what DLCO level puts a big red flag up in Chicago.
I have used one that is less than 40% with the red flag up for me.
The data you presented only showed a 10-point drop from normal.
What guideline do you use before you tell the patient and the refer-
ring doctors that this is a very high-risk patient?
Dr Ferguson. I try to be cautious when I am talking about
specific numbers. In Alex Brunelli’s study, they used a predicted
postoperative DLCO cutoff of 40% for distinguishing high-risk pa-
tients. That is what we use in general to distinguish between
much higher risk than so-called average risk, but it is really incre-
mental all the way. We will go so far as to operate on patients with
a postoperative predicted DLCO of maybe 30% if they seem other-
wise pretty vigorous. Everything else has to be taken into account
as well as this one number.
Dr Carolyn Reed (Charleston, SC). I think that also pertains to
my question. A couple weeks ago we had a patient with FVC/FEV1
80% of predicted, DLCO less than 40% of predicted, maximum1302 The Journal of Thoracic and Cardiovascular Soxygen consumption 20, and the patient had to have a lobectomy
to get the cancer out. Would you offer that patient a lobectomy?
Dr Ferguson.Given that DLCO, exercise testing is the additional
test I would do, and if that was as good as 20, yes, I would go with
the lobectomy.
Dr Richard Whyte (Stanford, Calif). Dr Ferguson, I have
1 question. You used the term a couple of times that the DLCO
was the strongest predictor of increased morbidity. You looked at
the P value on that. The P value was very low, but you had other
issues there that had a much higher relative risk that were still
highly statistically significant. I am wondering why you say this
is the most sensitive or this is the least likely to be a random predic-
tor. I would say that perhaps it is not the most important predictor of
a bad outcome. Could you comment on that?
Dr Ferguson. I am not a statistician. The P value is substan-
tially less than .0001, and that is the only reason we say it is the
strongest predictor. In our work with our own database in doing
backward elimination multivariable analysis, it does arise often-
times as the only predictor because most of those other things
fall out. You have to be a little careful about looking at the odds
ratios and comparing them because they are based on a variety
of different incremental changes for continuous variables. Some-
how, those have to be matched up to enable a head-to-head com-
parison. What we have elected to do sometimes is to measure
effects of a 10-year change in age, a 10-point difference in DLCO,
and so on. Whether those changes are equal to a 1-point increase
in creatinine or to a change from no hypertension to hypertension
is very hard to determine.
Dr Tara Karamlou (Portland, Ore). If I understand your find-
ings, you advocate that DLCO is able to be generalized to the entire
population. Yet in one of your earlier slides, you showed that induc-
tion chemotherapy and radiotherapy as well as, I believe, mortality,
were significantly different although you mention not importantly
different from a clinical perspective between the patients who
had DLCO measured and the subgroup who did not. Can you defend
that statement? Could it be more accurate to say that DLCO might be
more useful in patients who perhaps are going to be getting neoad-
juvant therapy or within the subgroup where you are actually mea-
suring it from your study?
Dr Ferguson. We do not have numbers of 5.5 million as in the
cardiac database, but 5500 patients is a large enough group of pa-
tients to demonstrate statistically significant differences between
the DLCO and noDLCO groups but not important clinical differences.
For example, there is difference in FEV1, but it was only 2 percent-
age points. I do think, though, it is important that we focus on DLCO
measurement in patients undergoing induction therapy, because
a number of people have demonstrated a substantial decrease in
DLCO as a result of induction chemotherapy and radiation therapy.
In our population, we measure DLCO, sometimes on multiple occa-
sions, until the DLCO gets back toward normal before we will sub-
ject them to surgery.urgery c December 2009
